Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MAIA Biotechnology, Inc.MAIA · Entity 6919 | Chief Financial Officer | May 31, 2023 | June 05, 2023 |
| NEXGEL, INC.NXGL · Entity 8400 | Chief Financial Officer | January 01, 2025 | January 06, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MAIA Biotechnology, Inc.
Report date May 31, 2023 · Filed June 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.50 · Expires 2032-05-30 | Direct | 69,075 |
Reported balance
After 2023-05-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-05-31 · Grant · Acquired 69,075 · Balance 69,075 F1: The stock options, granted on May 31, 2023 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options, granted on May 31, 2023 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.
NEXGEL, INC.
Report date January 01, 2025 · Filed January 06, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,082 |
Reported balance
Holding disclosure · report date 2025-01-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 4,082 |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.83 · Expires 2035-01-02 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2025-01-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: This stock options were granted to the Reporting Person on January 2, 2025 in connection with his appointment as the Issuer's Chief Financial Officer. The stock options vests as follows: (i) 25,000 shares of Common Stock vest on September 1, 2025; and (ii) the remaining 75,000 shares of Common Stock vest equally per month on the last day of each month for thirty-six months beginning on October 31, 2025 (with 2,084 shares vesting per month and 2,060 shares vesting on month thirty-six due to rounding adjustments); provided the Reporting Person is employed on the applicable vesting date by the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock options were granted to the Reporting Person on January 2, 2025 in connection with his appointment as the Issuer's Chief Financial Officer. The stock options vests as follows: (i) 25,000 shares of Common Stock vest on September 1, 2025; and (ii) the remaining 75,000 shares of Common Stock vest equally per month on the last day of each month for thirty-six months beginning on October 31, 2025 (with 2,084 shares vesting per month and 2,060 shares vesting on month thirty-six due to rounding adjustments); provided the Reporting Person is employed on the applicable vesting date by the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 31, 2023 Filed Jun 5, 2023 21:20 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 69,075 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001127602-23-017881 · form4.xml · derivative · entry 1 MCGUIRE JOSEPH F · CIK 0001243988 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,075 Underlying: Common Stock · 69,075 shares Expires 2032-05-30 F1 · derivative.exercise_date: The stock options, granted on May 31, 2023 pursuant to MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date. Read SEC document |
| April 27, 2023 Filed Apr 28, 2023 10:52 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 4,400 | $2.25 | $9,900.00 |
DisclosureSEC source: 0001127602-23-013714 · form4.xml · nonDerivative · entry 1 MCGUIRE JOSEPH F · CIK 0001243988 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,400 F1 · kind: These shares were purchased by the reporting person in the issuer's follow-on offering, which closed on April 27, 2023. Read SEC document |
| March 08, 2023 Filed Mar 10, 2023 22:13 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 100,000 | $0.00 Strike: $4.10 | $0.00 |
DisclosureSEC source: 0001127602-23-009777 · form4.xml · derivative · entry 1 MCGUIRE JOSEPH F · CIK 0001243988 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-03-08 F1 · derivative.exercise_date: The stock options, granted on March 8, 2023 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest on a 4-year vesting schedule, with 25% of the options to vest on the first anniversary of the date of grant and the remaining options to vest ratably monthly thereafter for 36 months. Read SEC document |
| September 16, 2022 Filed Sep 20, 2022 15:17 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | GrantStock Options · Derivative | 100,000 | $0.00 Strike: $3.56 | $0.00 |
DisclosureSEC source: 0001127602-22-022738 · form4.xml · derivative · entry 1 MCGUIRE JOSEPH F · CIK 0001243988 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-09-16 F1 · derivative.exercise_date: The stock options, granted on September 16, 2022 pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest on a 4-year vesting schedule, with 25% of the options to vest on the first anniversary of the date of grant and the remaining options to vest ratably monthly thereafter for 36 months. Read SEC document |
| August 01, 2022 Filed Aug 2, 2022 22:32 UTC | MAIA Biotechnology, Inc. MAIA · Entity 6919 | PurchaseCommon Stock | 5,000 | $5.00 | $25,000.00 |
DisclosureSEC source: 0000899243-22-027453 · doc4.xml · nonDerivative · entry 1 MCGUIRE JOSEPH F · CIK 0001243988 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · kind: These shares were purchased by the reporting person in the issuer's initial public offering, which closed on August 1, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.